Influence of PD-1 inhibitor pembrolizumab on T lymphocyte subsets and NK cells in patients with late stage non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2017.03.003
- VernacularTitle:PD-1抑制剂派姆单抗对晚期非小细胞肺癌T淋巴细胞亚群及NK细胞的影响
- Author:
Deliang HUANG
;
Zhongping YAO
;
Weizhong ZHANG
- Keywords:
Immunosuppressive agents;
Carcinoma,non-small-cell lung;
T lymphocyte subsets;
Treatment outcome;
PD-1 inhibitor
- From:
Journal of International Oncology
2017;44(3):169-172
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the changes of T lymphocyte subsets and natural killer (NK) cells in patients with late stage non-small cell lung cancer (NSCLC) before and after treatment with PD-1 inhibitor and its clinical effect.Methods Totally 23 patients with NSCLC in Guangzhou Modern Hospital from January 2015 to January 2016 were collected.All patients were given 6 cycles of PD-1 inhibitor treatment after chemotherapy or targeted drug treatment failure.Peripheral venous blood was collected before and after treatment to detect the percentage of CD3 +,CD4 +,CD8 + and NK cells in peripheral blood lymphocytes.The curative effects were evaluated by chest CT after treatment of 2,4,6 cycles.Results Compared with before treatment,the proportions of CD3+ (69.56％ ±7.81％ vs.63.91％ ±6.43％,t =2.679,P =0.005),CD4+ (39.01％ ±4.98％ vs.36.09％ ±4.77％,t =2.031,P =0.024) and CD4+/CD8+ (1.82 ±0.48 vs.1.49 ± 0.32,t =2.743,P =0.004) were increased after treatment,with significant differences.While compared with before treatment,the proportions of CD8 + (24.08％ ± 5.13％ vs.26.04％ ± 6.44％,t =1.142,P =0.130) and NK cells (22.68 ％ ± 9.56％ vs.21.45 ％ ± 10.01％,t =0.426,P =0.337) had little changes,with no significant differences.There were 3 patients with complete remission,10 patients with partial remission,8 patients with stable disease and 2 patients with progressive disease when completing 6 cycles of PD-1 inhibitor treatment.Ten patients showed untoward effects such as mild sleepiness,thirst,tussis,pruritus and rash,and they were well tolerable.Conclusion PD-1 inhibitor can improve the patient's cellular immune function,and can achieve a more satisfactory short-term efficacy and acceptable adverse reactions,which maybe bring new hopes for patients with NSCLC.
